Wieser H Gregor, Ortega Marcos, Friedman Alon, Yonekawa Yasuhiro
Department of Neurology, University Hospital Zurich, Switzerland.
J Neurosurg. 2003 Apr;98(4):751-63. doi: 10.3171/jns.2003.98.4.0751.
Analyses of the results of surgery for epilepsy are hindered by inconsistent classifications of seizure outcome, small numbers of patients, and short postoperative follow-up periods. The authors conducted a retrospective study with a reassessment of the long-term seizure outcomes in patients who underwent selective amygdalohippocampectomy (SelAH) for pharmacotherapy-resistant mesial temporal lobe epilepsy (MTLE) at the Zurich University Hospital from 1975 to 1999.
Year-by-year data and the last available data on seizure outcomes were retrospectively assessed for 369 consecutively surgically treated patients who had participated in a follow-up period longer than 1 year as of 1999 and whose outcomes were classified according to the Engel scale and the proposed new International League Against Epilepsy (ILAE) scale. Patients were grouped into nonlesional and lesional MTLE groups depending on whether they harbored a gross anatomical lesion that caused the MTLE. Differentiation was made between curative and palliative operations. Complications related to surgery are reported for 453 patients who underwent SelAH and participated in more than 3 months of follow-up review. The last available outcome data according to the Engel scale were found to be generally similar to those of the new ILAE classification, with 66.9% of patients free from disabling seizures (Engel Class I) compared with 57.1% who were completely seizure and aura free (ILAE Class 1). The last available data on seizure outcome were not significantly different between patients in the lesional and nonlesional MTLE groups. In the lesional group, seizure outcomes were significantly better when patients underwent surgery early in the course of the disease. Overall, 70% of the patients received reductions in their antiepileptic drug treatment at the time of the last available follow-up review. Complications related to the surgical procedures were rare.
The authors conclude that SelAH is a safe and effective surgical procedure for MTLE.
癫痫手术结果的分析受到癫痫发作结果分类不一致、患者数量少以及术后随访期短的阻碍。作者进行了一项回顾性研究,重新评估了1975年至1999年在苏黎世大学医院接受选择性杏仁核海马切除术(SelAH)治疗药物难治性内侧颞叶癫痫(MTLE)患者的长期癫痫发作结果。
对369例连续接受手术治疗的患者进行回顾性评估,这些患者截至1999年参与了超过1年的随访期,其结果根据恩格尔量表和新提议的国际抗癫痫联盟(ILAE)量表进行分类。根据患者是否存在导致MTLE的大体解剖病变,将患者分为非病变性和病变性MTLE组。区分了根治性手术和姑息性手术。报告了453例接受SelAH并参与了超过3个月随访复查患者的手术相关并发症。根据恩格尔量表得出的最后可用结果数据总体上与新的ILAE分类结果相似,66.9%的患者无致残性癫痫发作(恩格尔I级),而57.1%的患者完全无癫痫发作和先兆(ILAE 1级)。病变性和非病变性MTLE组患者的最后可用癫痫发作结果数据无显著差异。在病变性组中,患者在疾病早期接受手术时癫痫发作结果明显更好。总体而言,在最后一次可用随访复查时,70%的患者抗癫痫药物治疗有所减少。与手术操作相关的并发症很少见。
作者得出结论,SelAH是一种治疗MTLE安全有效的手术方法。